UPDATE : Tuesday, November 19, 2019
Pfizer fails to cut participants in Xeljanz’ post-marketing surveillance
Pfizer Korea has failed to reduce the number of target participants in post...
by Lee Hye-seon  |  2019-07-08 16:39
Eutilex wins patent for immunotherapy in Australia
Eutilex said that it has patented EU101, an immunotherapy targeting 4-1BB, ...
by Lee Han-soo  |  2019-07-08 14:27
Yuhan invests ₩6 billion in Imnewrun Biosciences
Yuhan Corp. said it has invested 6 billion won ($5.09 million) in Imnewrun ...
by Lee Han-soo  |  2019-07-08 12:05
Dong-A ST, Dongwha Pharm lose status of innovative drugmaker
Dong-A ST and Dongwha Pharm failed to renew the state-designated certificat...
by Jeong Sae-im  |  2019-07-05 16:00
Lilly aims to reshape Korea’s breast cancer treatment market
Lilly Korea is seeking to reshape Korea’s breast cancer treatment market on...
by Lee Han-soo  |  2019-07-05 16:00
‘Truvada will improve Korea's HIV treatment environment’
Gilead Science is strengthening its position in the local human immunodefic...
by Lee Han-soo  |  2019-07-04 10:53
Janssen nixes deal with Hanmi over antidiabetic obesity drug
Janssen, a subsidiary of Johnson & Johnson, has decided to return the devel...
by Jeong Sae-im  |  2019-07-04 10:52
Bukwang, UK university to co-develop Parkinson’s disease treatment
Bukwang Pharmaceutical has signed a multibillion-won contract with Universi...
by Lee Han-soo  |  2019-07-03 15:03
Handok releases Fabry disease treatment
Handok said Tuesday that it has rolled out Galafold, a Fabry disease treatm...
by Lee Han-soo  |  2019-07-02 16:19
26 new drugs approved in H1
Twenty-six new pharmaceutical products received approval in Korea in the fi...
by Lee Hye-seon  |  2019-07-02 14:31
[News Focus]Yuhan pulled off $3.1 billion licensing deals in one year. How?
Yuhan Corp. recently made headlines by signing an $870 million licensing de...
by Jeong Sae-im  |  2019-07-02 12:11
Huons launches new osteoarthritis treatment
Huons said that it has launched “Hi Hyal Once,” an osteoarthritis treatment...
by Lee Han-soo  |  2019-07-01 15:13
Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz
The Korean branch of Eli Lilly said that it had gained additional reimburse...
by Lee Han-soo  |  2019-07-01 14:27
BMS Korea files administrative suit to appeal Eliquis price cut
The price reduction of BMS Korea Pharmaceutical’s blood thinner Elidquis ha...
by Kim Yun-mi  |  2019-07-01 14:16
Yuhan signs $870 million licensing deal with Boehringer Ingelheim
Yuhan announced a joint development and licensing agreement with Boehringer...
by Lee Han-soo  |  2019-07-01 14:09
'Proteogenomics will improve ability to prevent, diagnose and treat cancer at molecular level'
With recent advancements in sequencing technologies, scientists are no long...
by Lee Han-soo  |  2019-06-28 17:43
Lilly anticipates Trulicity’s growth as GLP-1 receptor antagonists get popular
As physicians have increasingly recommended glucagon-like peptide-1 (GLP-1)...
by Kim Yun-mi  |  2019-06-28 16:12
Samsung Bioepis readies phase-3 trial on Soliris biosimilar
Samsung Bioepis is speeding up to develop a biosimilar of Soliris (eculizum...
by Lee Hye-seon  |  2019-06-27 17:14
Eutilex unveils immunotherapy development strategy
Eutilex presented its immunotherapy development strategy during the "Global...
by Lee Han-soo  |  2019-06-27 16:51
Voluntary nullifications of drug license tripled in H1
An increasing number of pharmaceutical companies voluntarily canceled the l...
by Lee Hye-seon  |  2019-06-26 14:25
Back to Top